Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet

Clinical Cancer Research

Volumn 7, Issue 2, 2001, Pages 223-225

  Gabizon, A A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME;

CANCER PATIENT; CANCER RESEARCH; DRUG DELIVERY SYSTEM; DRUG TARGETING; EDITORIAL; ENDOTHELIUM CELL; PRIORITY JOURNAL;

DRUG DELIVERY SYSTEMS; HUMANS; INDIUM RADIOISOTOPES; LIPOSOMES; NEOPLASMS; PENTETIC ACID; TISSUE DISTRIBUTION;

EID: 0035120280     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. Diffusion of univalent ions across the lamellae of swollen phospholipids
2. Drug-carrier potential of liposomes in cancer chemotherapy
3. Liposome targeting in vivo: Problems and opportunities
4. Liposomes as drug carriers in cancer chemotherapy
5. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs
6. Fate and behavior of liposomes in vivo: A review of controlling factors
7. Large unilamellar liposomes with low uptake into the reticuloendothelial system
8. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors
9. The role of surface charge and hydrophilic groups on liposome clearance in vivo
10. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
11. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
12. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles
13. Liposomes for the sustained drug release in vivo
14. Sterically stabilized liposomes
15. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times
16. Tumor accumulation of novel RES-avoiding liposomes
17. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
18. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy
19. Drug-polymer conjugates: Potential for improved chemotherapy
20. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice
21. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft
22. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases
23. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled PEGylated liposomes
24. Biodistribution and pharmacokinetics of 111 In-DTPA-labelled PEGylated liposomes in a human tumour xenograft model: Implications for novel targeting strategies
25. 67Gallium-labeled liposomes with prolonged circulation: Preparation and potential as nuclear imaging agents
26. Doxil (Caelyx). An exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
27. Correlation of toxicity with pharmacokinetics of PEGylated liposomal doxorubicin (Doxil) in metastatic breast cancer
28. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
29. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy
30. 111In-DTPA-labelled PEGylated liposomes in a human tumour xenograft model
31. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin
32. Delivery of molecular and cellular medicine to solid tumors
33. PEGylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy
34. Studies on the in vivo disposition of Adriamycin in human tumors which exhibit different responses to the drug